NeuroBo Pharmaceuticals (NRBO) Announces Strategic Realignment, Changes Name to MetaVia (MTVA) Nov 18, 2024 08:01AM
NeuroBo Pharmaceuticals (NRBO) Misses Q3 EPS by 55c Nov 7, 2024 05:19PM
NeuroBo Pharmaceuticals (NRBO) Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Trial of DA-1726 Sep 30, 2024 08:01AM
NeuroBo Pharmaceuticals (NRBO) Misses Q2 EPS by 185c Aug 15, 2024 04:47PM
NeuroBo Pharmaceuticals (NRBO) Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity Aug 6, 2024 08:01AM


Jul 30, 2024 08:02AM NeuroBo Pharmaceuticals (NRBO) Announces Exclusive License Agreement with MThera Pharma for NB-01
Jul 18, 2024 08:23AM NeuroBo Pharmaceuticals (NRBO) Files for up to 17.18M Share Offering by Selling Stockholders
Jun 26, 2024 09:07AM NeuroBo Pharmaceuticals (NRBO) Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
Jun 24, 2024 08:01AM NeuroBo Pharmaceuticals (NRBO) Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering